Topical timolol for superficial cutaneous infantile hemangiomas in very preterm infants

Introduction. Infantile hemangiomas (IHs) occur 3 to 4 times more frequently in preterm infants than in those born at term. Yet, data about efficacy and safety of topical therapy for IHs in preterm infants, especially in those born with very low gestational age (less than 33 gestational weeks) is very scarce. Case report. We reported five very preterm girls treated with topical timolol maleate 0.5% gel for superficial cutaneous IHs. In four infants topical timolol was applied on a single IH each, and in one infant two IHs were treated. Out of six treated IHs, one was located on the face, four on the trunk and one on the leg. They were regularly monitored for IH involution and potential adverse effects of timolol for 6?13 months of local treatment. Good therapeutic effect was achieved in all the presented infants, with no adverse effects related to topical administration of timolol-maleate. Conclusion. Topical timolol is an effective and safe therapy for superficial cutaneous infantile hemangiomas in very preterm infants. The treatment should be discussed in detail with parents and individualized management plan should be tailored for each infant in order to maximize the chances of a successful outcome, while avoiding adverse effects.

[1]  I. García-Doval,et al.  Study of Cognitive Function in Children Treated with Propranolol for Infantile Hemangioma , 2017, Pediatric dermatology.

[2]  L. Su,et al.  Topical Application of 0.5% Timolol Maleate Hydrogel for the Treatment of Superficial Infantile Hemangioma , 2017, Front. Oncol..

[3]  M. Koh,et al.  Comparison of Two Formulations of Topical Timolol for the Treatment of Infantile Hemangiomas , 2017, Pediatric dermatology.

[4]  A. Budiyanto,et al.  Topical Timolol Maleate 0.5% for Infantile Hemangioma: Its Effectiveness Compared to Ultrapotent Topical Corticosteroids - A Single-Center Experience of 278 Cases , 2016, Dermatology.

[5]  K. Holland,et al.  Adverse Events in Young and Preterm Infants Receiving Topical Timolol for Infantile Hemangioma , 2016, Pediatric dermatology.

[6]  W. Hoffman,et al.  Breast Hypoplasia as a Complication of an Untreated Infantile Hemangioma , 2016, Pediatric dermatology.

[7]  J. Bernabéu-Wittel,et al.  Effectiveness of Propranolol in the Treatment of Infantile Hemangioma Beyond the Proliferation Phase , 2015, Pediatric dermatology.

[8]  E. Pope,et al.  Propranolol and central nervous system function: potential implications for paediatric patients with infantile haemangiomas , 2015, The British journal of dermatology.

[9]  C. Poets,et al.  Incidence and treatment of infantile haemangioma in preterm infants , 2014, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[10]  V. Catanzarite,et al.  Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies , 2014, The British journal of dermatology.

[11]  R. Hegazy,et al.  Propranolol and infantile hemangiomas: different routes of administration, a randomized clinical trial. , 2013, European journal of dermatology : EJD.

[12]  I. Frieden,et al.  Haemangioma: clinical course, complications and management , 2013, The British journal of dermatology.

[13]  Min-lian Huang,et al.  Treatment of superficial infantile hemangiomas with timolol: Evaluation of short-term efficacy and safety in infants , 2013, Experimental and therapeutic medicine.

[14]  O. Wargon,et al.  RCT of Timolol Maleate Gel for Superficial Infantile Hemangiomas in 5- to 24-Week-Olds , 2013, Pediatrics.

[15]  C. Poets,et al.  Topical Timolol for Small Hemangiomas of Infancy , 2013, Pediatric dermatology.

[16]  Hua Wang,et al.  A Retrospective Study of Propranolol Therapy in 109 Infants with Infantile Hemangioma , 2013, Pediatric dermatology.

[17]  K. Holland,et al.  Initiation and Use of Propranolol for Infantile Hemangioma: Report of a Consensus Conference , 2013, Pediatrics.

[18]  D. Zurakowski,et al.  Infantile Hemangioma: Clinical Assessment of the Involuting Phase and Implications for Management , 2012, Plastic and reconstructive surgery.

[19]  J. Kazandjieva,et al.  Topical Treatment of Infantile Hemangiomas – Where Are We Now? / Topikalni tretman infantilnih hemangioma – gde smo danas? , 2011 .

[20]  J. Kleber,et al.  Propranolol Therapy in 55 Infants with Infantile Hemangioma: Dosage, Duration, Adverse Effects, and Outcome , 2011, Pediatric dermatology.

[21]  W. Hop,et al.  Scoring the proliferative activity of haemangioma of infancy: the Haemangioma Activity Score (HAS) , 2011, Clinical and experimental dermatology.

[22]  R. Hegazy,et al.  Oral propranolol: an effective, safe treatment for infantile hemangiomas. , 2011, European journal of dermatology : EJD.

[23]  O. Wargon,et al.  A Randomized Controlled Trial of Propranolol for Infantile Hemangiomas , 2011, Pediatrics.

[24]  C. Zeebregts,et al.  Untreated Hemangiomas: Growth Pattern and Residual Lesions , 2011, Plastic and reconstructive surgery.

[25]  A. Zvulunov,et al.  Oral Propranolol Therapy for Infantile Hemangiomas Beyond the Proliferation Phase: A Multicenter Retrospective Study , 2011, Pediatric dermatology.

[26]  N. Laforgia,et al.  Severe Hypoglycemia During Successful Treatment of Diffuse Hemangiomatosis with Propranolol , 2010, Pediatric dermatology.

[27]  Suqin Guo,et al.  Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. , 2010, Archives of ophthalmology.

[28]  I. Frieden,et al.  Comparison of infantile hemangiomas in preterm and term infants: a prospective study. , 2008, Archives of dermatology.

[29]  F. Boralevi,et al.  Propranolol for severe hemangiomas of infancy. , 2008, The New England journal of medicine.